Home > Publications database > Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis. > print

001     177752
005     20240303004942.0
024 7 _ |a 10.1093/noajnl/vdab109
|2 doi
024 7 _ |a pmid:34859225
|2 pmid
024 7 _ |a pmc:PMC8633655
|2 pmc
024 7 _ |a altmetric:157459171
|2 altmetric
037 _ _ |a DKFZ-2021-02793
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Whitehouse, Jacqueline P
|b 0
245 _ _ |a Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis.
260 _ _ |a Oxford
|c 2021
|b Oxford University Press
264 _ 1 |3 online
|2 Crossref
|b Oxford University Press (OUP)
|c 2021-08-12
264 _ 1 |3 print
|2 Crossref
|b Oxford University Press (OUP)
|c 2021-01-01
264 _ 1 |3 print
|2 Crossref
|b Oxford University Press (OUP)
|c 2021-01-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692701491_25035
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Cranial radiation therapy is essential in treating many pediatric cancers, especially brain tumors; however, its use comes with the risk of developing second malignancies. Cranial radiation-induced gliomas (RIGs) are aggressive high-grade tumors with a dismal prognosis, for which no standard therapy exists. A definitive molecular signature for RIGs has not yet been established. We sought to address this gap by performing a systematic review and meta-analysis of the molecular features of cranial RIGs.A systematic review of the literature was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Articles and case reports that described molecular analyses of cranial radiation-induced high-grade gliomas were identified and evaluated, and data extracted for collation.Of 1727 records identified, 31 were eligible, containing 102 unique RIGs with molecular data. The most frequent genetic alterations in RIGs included PDGFRA or TP53 mutations, PDGFRA or CDK4 amplifications, and CDKN2A deletion, along with 1q gain, 1p loss and 13q loss. Of note, mutations in ACVR1, EGFR, H3F3A, HIST1H3B, HIST1H3C, IDH2, SMARCB1 or the TERT promoter were not observed. A comparative analysis revealed that RIGs are molecularly distinct from most other astrocytomas and gliomas and instead align most closely with the pedGBM_RTK1 subgroup of pediatric glioblastoma.This comprehensive analysis highlights the major molecular features of RIGs, demonstrates their molecular distinction from many other astrocytomas and gliomas, and reveals potential genetic drivers and therapeutic targets for this currently fatal disease.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
542 _ _ |i 2021-08-12
|2 Crossref
|u https://creativecommons.org/licenses/by-nc/4.0/
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Radiation-induced glioma
|2 Other
650 _ 7 |a cancer
|2 Other
650 _ 7 |a molecular
|2 Other
650 _ 7 |a pediatric
|2 Other
650 _ 7 |a radiation
|2 Other
700 1 _ |a Howlett, Meegan
|b 1
700 1 _ |a Federico, Aniello
|0 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9
|b 2
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 3
|u dkfz
700 1 _ |a Endersby, Raelene
|0 0000-0003-3554-2769
|b 4
700 1 _ |a Gottardo, Nicholas G
|b 5
773 1 8 |a 10.1093/noajnl/vdab109
|b Oxford University Press (OUP)
|d 2021-01-01
|n 1
|3 journal-article
|2 Crossref
|t Neuro-Oncology Advances
|v 3
|y 2021
|x 2632-2498
773 _ _ |a 10.1093/noajnl/vdab109
|g Vol. 3, no. 1, p. vdab109
|0 PERI:(DE-600)3009682-0
|n 1
|p vdab109
|t Neuro-oncology advances
|v 3
|y 2021
|x 2632-2498
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177752
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-09-23T13:25:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-09-23T13:25:59Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-09-23T13:25:59Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-12
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1016/j.neuchi.2018.01.006
|9 -- missing cx lookup --
|1 Bernier
|p 83 -
|2 Crossref
|t Neurochirurgie.
|v 67
|y 2021
999 C 5 |a 10.1016/j.ctrv.2008.09.002
|9 -- missing cx lookup --
|1 Fossati
|p 79 -
|2 Crossref
|t Cancer Treat Rev.
|v 35
|y 2009
999 C 5 |a 10.3389/fonc.2013.00073
|9 -- missing cx lookup --
|1 Braunstein
|p 73 -
|2 Crossref
|t Front Oncol.
|v 3
|y 2013
999 C 5 |a 10.1002/cncr.33507
|9 -- missing cx lookup --
|1 Nantavithya
|p 2368 -
|2 Crossref
|t Cancer.
|v 127
|y 2021
999 C 5 |a 10.1093/jnci/djj411
|9 -- missing cx lookup --
|1 Neglia
|p 1528 -
|2 Crossref
|t J Natl Cancer Inst.
|v 98
|y 2006
999 C 5 |a 10.1016/j.ijrobp.2007.12.018
|9 -- missing cx lookup --
|1 Paulino
|p 1381 -
|2 Crossref
|t Int J Radiat Oncol Biol Phys.
|v 71
|y 2008
999 C 5 |a 10.1200/JCO.2009.27.0090
|9 -- missing cx lookup --
|1 Taylor
|p 5287 -
|2 Crossref
|t J Clin Oncol.
|v 28
|y 2010
999 C 5 |a 10.1200/JCO.1998.16.12.3761
|9 -- missing cx lookup --
|1 Walter
|p 3761 -
|2 Crossref
|t J Clin Oncol.
|v 16
|y 1998
999 C 5 |a 10.1016/j.clon.2013.06.007
|9 -- missing cx lookup --
|1 Lomax
|p 578 -
|2 Crossref
|t Clin Oncol (R Coll Radiol).
|v 25
|y 2013
999 C 5 |a 10.1590/S1415-475738420150019
|9 -- missing cx lookup --
|1 Borrego-Soto
|p 420 -
|2 Crossref
|t Genet Mol Biol.
|v 38
|y 2015
999 C 5 |a 10.1080/09553002.2020.1807641
|9 -- missing cx lookup --
|1 Liu
|p 1329 -
|2 Crossref
|t Int J Radiat Biol.
|v 96
|y 2020
999 C 5 |a 10.1038/sj.onc.1206881
|9 -- missing cx lookup --
|1 Suzuki
|p 6988 -
|2 Crossref
|t Oncogene.
|v 22
|y 2003
999 C 5 |a 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7
|9 -- missing cx lookup --
|1 Cahan
|p 3 -
|2 Crossref
|t Cancer.
|v 1
|y 1948
999 C 5 |a 10.1007/s00381-008-0631-7
|9 -- missing cx lookup --
|1 Pettorini
|p 793 -
|2 Crossref
|t Childs Nerv Syst.
|v 24
|y 2008
999 C 5 |a 10.1016/j.wneu.2016.09.094
|9 -- missing cx lookup --
|1 Yamanaka
|p 635 -
|2 Crossref
|t World Neurosurg
|v 97
|y 2017
999 C 5 |a 10.1007/s10143-016-0786-8
|9 -- missing cx lookup --
|1 Yamanaka
|p 719 -
|2 Crossref
|t Neurosurg Rev.
|v 41
|y 2018
999 C 5 |a 10.1016/j.wneu.2014.12.009
|9 -- missing cx lookup --
|1 Elsamadicy
|p 530 -
|2 Crossref
|t World Neurosurg.
|v 83
|y 2015
999 C 5 |a 10.1097/nen.0b013e3181257190
|9 -- missing cx lookup --
|1 Donson
|p 740 -
|2 Crossref
|t J Neuropathol Exp Neurol.
|v 66
|y 2007
999 C 5 |a 10.1186/s40478-018-0570-9
|9 -- missing cx lookup --
|1 Gits
|p 67 -
|2 Crossref
|t Acta Neuropathol Commun.
|v 6
|y 2018
999 C 5 |a 10.1038/nature26000
|9 -- missing cx lookup --
|1 Capper
|p 469 -
|2 Crossref
|t Nature.
|v 555
|y 2018
999 C 5 |a 10.1136/bmj.n160
|9 -- missing cx lookup --
|1 Page
|p n160 -
|2 Crossref
|t BMJ
|v 372
|y 2021
999 C 5 |a 10.1097/00006123-199702000-00034
|9 -- missing cx lookup --
|1 Tada
|p 393 -
|2 Crossref
|t Neurosurgery.
|v 40
|y 1997
999 C 5 |a 10.2176/nmc.38.287
|9 -- missing cx lookup --
|1 Matsumura
|p 287 -
|2 Crossref
|t Neurol Med Chir (Tokyo).
|v 38
|y 1998
999 C 5 |a 10.1016/S0002-9440(10)65397-7
|9 -- missing cx lookup --
|1 Brat
|p 1431 -
|2 Crossref
|t Am J Pathol.
|v 154
|y 1999
999 C 5 |1 Yang
|y 2005
|2 Crossref
|o Yang 2005
999 C 5 |a 10.1227/01.neu.0000303207.92617.4e
|9 -- missing cx lookup --
|1 Berman
|p E1099; discussion E1099 -
|2 Crossref
|t Neurosurgery.
|v 61
|y 2007
999 C 5 |a 10.1007/s00381-006-0199-z
|9 -- missing cx lookup --
|1 Romeike
|p 185 -
|2 Crossref
|t Childs Nerv Syst.
|v 23
|y 2007
999 C 5 |1 Gessi
|y 2008
|2 Crossref
|o Gessi 2008
999 C 5 |a 10.1007/s11060-008-9565-x
|9 -- missing cx lookup --
|1 Salvati
|p 169 -
|2 Crossref
|t J Neurooncol.
|v 89
|y 2008
999 C 5 |a 10.1007/s11060-008-9570-0
|9 -- missing cx lookup --
|1 Sasayama
|p 315 -
|2 Crossref
|t J Neurooncol.
|v 88
|y 2008
999 C 5 |a 10.1590/S0004-282X2009000400028
|9 -- missing cx lookup --
|1 García-Navarro
|p 707 -
|2 Crossref
|t Arq Neuropsiquiatr.
|v 67
|y 2009
999 C 5 |a 10.1007/s11060-010-0166-0
|9 -- missing cx lookup --
|1 Kamide
|p 299 -
|2 Crossref
|t J Neurooncol.
|v 100
|y 2010
999 C 5 |a 10.1200/JCO.2009.26.7252
|9 -- missing cx lookup --
|1 Paugh
|p 3061 -
|2 Crossref
|t J Clin Oncol.
|v 28
|y 2010
999 C 5 |a 10.1111/j.1440-1789.2011.01198.x
|9 -- missing cx lookup --
|1 Ohba
|p 606 -
|2 Crossref
|t Neuropathology.
|v 31
|y 2011
999 C 5 |a 10.3109/02688697.2012.741740
|9 -- missing cx lookup --
|1 Khoo
|p 259 -
|2 Crossref
|t Br J Neurosurg.
|v 27
|y 2013
999 C 5 |a 10.1007/s11060-012-0925-1
|9 -- missing cx lookup --
|1 Mascelli
|p 477 -
|2 Crossref
|t J Neurooncol.
|v 109
|y 2012
999 C 5 |a 10.4103/0971-5851.133729
|9 -- missing cx lookup --
|1 Ahmed
|p 86 -
|2 Crossref
|t Indian J Med Paediatr Oncol.
|v 35
|y 2014
999 C 5 |a 10.1007/s10014-017-0292-x
|9 -- missing cx lookup --
|1 Nakao
|p 149 -
|2 Crossref
|t Brain Tumor Pathol.
|v 34
|y 2017
999 C 5 |1 Ng
|y 2017
|2 Crossref
|o Ng 2017
999 C 5 |a 10.3390/cancers12102937
|9 -- missing cx lookup --
|1 Whitehouse
|p 2937 -
|2 Crossref
|t Cancers (Basel)
|v 12
|y 2020
999 C 5 |a 10.1155/2018/4596812
|9 -- missing cx lookup --
|1 Izycka-Swieszewska
|p 4596812 -
|2 Crossref
|t Biomed Res Int.
|v 2018
|y 2018
999 C 5 |a 10.1007/s10014-018-0316-1
|9 -- missing cx lookup --
|1 Kajitani
|p 114 -
|2 Crossref
|t Brain Tumor Pathol.
|v 35
|y 2018
999 C 5 |a 10.1007/s00401-018-1845-8
|9 -- missing cx lookup --
|1 Phi
|p 939 -
|2 Crossref
|t Acta Neuropathol.
|v 135
|y 2018
999 C 5 |a 10.1097/NRL.0000000000000199
|9 -- missing cx lookup --
|1 Porter
|p 191 -
|2 Crossref
|t Neurologist.
|v 23
|y 2018
999 C 5 |1 Wang
|y 2018
|2 Crossref
|o Wang 2018
999 C 5 |a 10.1007/s00401-018-1906-z
|9 -- missing cx lookup --
|1 López
|p 139 -
|2 Crossref
|t Acta Neuropathol.
|v 137
|y 2019
999 C 5 |a 10.5114/fn.2019.83834
|9 -- missing cx lookup --
|1 Mucha-Małecka
|p 80 -
|2 Crossref
|t Folia Neuropathol.
|v 57
|y 2019
999 C 5 |a 10.1159/000511996
|9 -- missing cx lookup --
|1 Biswas
|p 409 -
|2 Crossref
|t Pediatr Neurosurg.
|v 55
|y 2020
999 C 5 |a 10.1007/s00401-020-02171-5
|9 -- missing cx lookup --
|1 Smith
|p 209 -
|2 Crossref
|t Acta Neuropathol.
|v 140
|y 2020
999 C 5 |a 10.1080/02688697.2021.1881445
|9 -- missing cx lookup --
|1 Woo
|p 1 -
|2 Crossref
|t Br J Neurosurg
|y 2021
999 C 5 |a 10.1097/MPH.0b013e3181e51403
|9 -- missing cx lookup --
|1 Madden
|p e272 -
|2 Crossref
|t J Pediatr Hematol Oncol.
|v 32
|y 2010
999 C 5 |a 10.1111/j.1440-1789.2011.01277.x
|9 -- missing cx lookup --
|1 Martin
|p 543 -
|2 Crossref
|t Neuropathology.
|v 32
|y 2012
999 C 5 |1 DeSisto
|y 25, 2019
|2 Crossref
|o DeSisto 25, 2019
999 C 5 |a 10.1111/his.12927
|9 -- missing cx lookup --
|1 Ikemura
|p 260 -
|2 Crossref
|t Histopathology.
|v 69
|y 2016
999 C 5 |a 10.1007/s00401-012-1031-3
|9 -- missing cx lookup --
|1 Liu
|p 615 -
|2 Crossref
|t Acta Neuropathol.
|v 124
|y 2012
999 C 5 |a 10.1093/jnen/nlv009
|9 -- missing cx lookup --
|1 Tanboon
|p 4 -
|2 Crossref
|t J Neuropathol Exp Neurol.
|v 75
|y 2016
999 C 5 |a 10.3346/jkms.2009.24.3.453
|9 -- missing cx lookup --
|1 Kim
|p 453 -
|2 Crossref
|t J Korean Med Sci.
|v 24
|y 2009
999 C 5 |a 10.1016/j.ccell.2017.08.017
|9 -- missing cx lookup --
|1 Mackay
|p 520 -
|2 Crossref
|t Cancer Cell
|v 32
|y 2017
999 C 5 |a 10.1016/0165-4608(94)90157-0
|9 -- missing cx lookup --
|1 Magnani
|p 77 -
|2 Crossref
|t Cancer Genet Cytogenet.
|v 75
|y 1994
999 C 5 |a 10.1200/JCO.2017.73.0242
|9 -- missing cx lookup --
|1 Sturm
|p 2370 -
|2 Crossref
|t J Clin Oncol.
|v 35
|y 2017
999 C 5 |a 10.1093/neuonc/noaa251
|9 -- missing cx lookup --
|1 Sievers
|p 34 -
|2 Crossref
|t Neuro-Oncology
|v 23
|y 2020
999 C 5 |a 10.1007/s00401-017-1710-1
|9 -- missing cx lookup --
|1 Korshunov
|p 507 -
|2 Crossref
|t Acta Neuropathol.
|v 134
|y 2017
999 C 5 |a 10.1002/ccr3.521
|9 -- missing cx lookup --
|1 Kato
|p 356 -
|2 Crossref
|t Clin Case Rep.
|v 4
|y 2016
999 C 5 |a 10.1093/neuonc/nou053
|9 -- missing cx lookup --
|1 Smoll
|p 1400 -
|2 Crossref
|t Neuro Oncol.
|v 16
|y 2014
999 C 5 |a 10.1007/s00401-016-1545-1
|9 -- missing cx lookup --
|1 Louis
|p 803 -
|2 Crossref
|t Acta Neuropathol.
|v 131
|y 2016
999 C 5 |a 10.3390/ijms21020685
|9 -- missing cx lookup --
|1 Arcella
|p 685 -
|2 Crossref
|t Int J Mol Sci
|v 21
|y 2020
999 C 5 |a 10.18632/oncotarget.588
|9 -- missing cx lookup --
|1 Jiao
|p 709 -
|2 Crossref
|t Oncotarget.
|v 3
|y 2012
999 C 5 |a 10.18632/oncotarget.1505
|9 -- missing cx lookup --
|1 Killela
|p 1452 -
|2 Crossref
|t Oncotarget.
|v 5
|y 2014
999 C 5 |a 10.1007/s10014-016-0260-x
|9 -- missing cx lookup --
|1 Takano
|p 107 -
|2 Crossref
|t Brain Tumor Pathol.
|v 33
|y 2016
999 C 5 |a 10.1007/s00401-013-1156-z
|9 -- missing cx lookup --
|1 Wiestler
|p 443 -
|2 Crossref
|t Acta Neuropathol.
|v 126
|y 2013
999 C 5 |a 10.1007/s00401-009-0550-z
|9 -- missing cx lookup --
|1 Korshunov
|p 401 -
|2 Crossref
|t Acta Neuropathol.
|v 118
|y 2009
999 C 5 |a 10.1007/s00018-011-0898-9
|9 -- missing cx lookup --
|1 Jones
|p 1799 -
|2 Crossref
|t Cell Mol Life Sci.
|v 69
|y 2012
999 C 5 |a 10.1002/path.2558
|9 -- missing cx lookup --
|1 Forshew
|p 172 -
|2 Crossref
|t J Pathol.
|v 218
|y 2009
999 C 5 |a 10.1038/ng.2682
|9 -- missing cx lookup --
|1 Jones
|p 927 -
|2 Crossref
|t Nat Genet.
|v 45
|y 2013
999 C 5 |a 10.1158/0008-5472.CAN-08-2097
|9 -- missing cx lookup --
|1 Jones
|p 8673 -
|2 Crossref
|t Cancer Res.
|v 68
|y 2008
999 C 5 |a 10.3389/fonc.2015.00237
|9 -- missing cx lookup --
|1 Vanan
|p 237 -
|2 Crossref
|t Front Oncol.
|v 5
|y 2015
999 C 5 |a 10.1038/nrc3811
|1 Jones
|9 -- missing cx lookup --
|2 Crossref
|t Nat Rev Cancer
|v 14
|y 2014
999 C 5 |a 10.1007/s00401-012-0998-0
|9 -- missing cx lookup --
|1 Khuong-Quang
|p 439 -
|2 Crossref
|t Acta Neuropathol.
|v 124
|y 2012
999 C 5 |a 10.1038/ng.1102
|9 -- missing cx lookup --
|1 Wu
|p 251 -
|2 Crossref
|t Nat Genet.
|v 44
|y 2012
999 C 5 |a 10.1007/s00401-018-1826-y
|9 -- missing cx lookup --
|1 Louis
|p 639 -
|2 Crossref
|t Acta Neuropathol.
|v 135
|y 2018
999 C 5 |a 10.3389/fonc.2015.00147
|9 -- missing cx lookup --
|1 Buczkowicz
|p 147 -
|2 Crossref
|t Front Oncol.
|v 5
|y 2015
999 C 5 |a 10.1038/ng.2938
|9 -- missing cx lookup --
|1 Wu
|p 444 -
|2 Crossref
|t Nat Genet.
|v 46
|y 2014
999 C 5 |a 10.1200/JCO.2009.25.5463
|9 -- missing cx lookup --
|1 Zarghooni
|p 1337 -
|2 Crossref
|t J Clin Oncol.
|v 28
|y 2010
999 C 5 |a 10.1158/1078-0432.CCR-12-3002
|9 -- missing cx lookup --
|1 Ohgaki
|p 764 -
|2 Crossref
|t Clin Cancer Res.
|v 19
|y 2013
999 C 5 |a 10.1016/j.cell.2013.09.034
|9 -- missing cx lookup --
|1 Brennan
|p 462 -
|2 Crossref
|t Cell.
|v 155
|y 2013
999 C 5 |a 10.1038/nature07385
|9 -- missing cx lookup --
|1 Cancer Genome Atlas Research N
|p 1061 -
|2 Crossref
|t Nature
|v 455
|y 2008
999 C 5 |a 10.1126/science.1164382
|9 -- missing cx lookup --
|1 Parsons
|p 1807 -
|2 Crossref
|t Science.
|v 321
|y 2008
999 C 5 |a 10.1016/j.ccr.2009.12.020
|9 -- missing cx lookup --
|1 Verhaak
|p 98 -
|2 Crossref
|t Cancer Cell.
|v 17
|y 2010
999 C 5 |a 10.1016/j.ccr.2012.08.024
|9 -- missing cx lookup --
|1 Sturm
|p 425 -
|2 Crossref
|t Cancer Cell.
|v 22
|y 2012
999 C 5 |a 10.1093/neuonc/noaa222.336
|9 -- missing cx lookup --
|1 Lucas
|p iii354 -
|2 Crossref
|t Neuro-Oncology
|v 22
|y 2020
999 C 5 |a 10.1002/ijc.30057
|9 -- missing cx lookup --
|1 Batista
|p 414 -
|2 Crossref
|t Int J Cancer.
|v 139
|y 2016
999 C 5 |a 10.1038/s41598-020-65272-x
|9 -- missing cx lookup --
|1 Mosaab
|p 8368 -
|2 Crossref
|t Sci Rep.
|v 10
|y 2020
999 C 5 |a 10.1093/jnci/93.16.1246
|9 -- missing cx lookup --
|1 Smith
|p 1246 -
|2 Crossref
|t J Natl Cancer Inst.
|v 93
|y 2001
999 C 5 |a 10.5301/JBM.5000045
|9 -- missing cx lookup --
|1 Carvalho
|p e120 -
|2 Crossref
|t Int J Biol Markers.
|v 29
|y 2014
999 C 5 |a 10.1093/neuonc/noab106
|9 -- missing cx lookup --
|1 Louis
|p 1231 -
|2 Crossref
|t Neuro Oncol.
|v 23
|y 2021
999 C 5 |a 10.1200/JCO.2018.36.15_suppl.10573
|9 -- missing cx lookup --
|1 Lucas
|p 10573 -
|2 Crossref
|t Journal of Clinical Oncology
|v 36
|y 2018
999 C 5 |a 10.1016/S0140-6736(98)11079-6
|9 -- missing cx lookup --
|1 Relling
|p 34 -
|2 Crossref
|t Lancet.
|v 354
|y 1999
999 C 5 |a 10.1227/01.NEU.0000064809.59806.E8
|9 -- missing cx lookup --
|1 Loeffler
|p 1436 -
|2 Crossref
|t Neurosurgery.
|v 52
|y 2003
999 C 5 |a 10.1093/neuonc/noaa222.313
|9 -- missing cx lookup --
|1 Váňová
|p iii349 -
|2 Crossref
|t Neuro-Oncology
|v 22
|y 2020
999 C 5 |a 10.1158/0008-5472.CAN-19-0680
|9 -- missing cx lookup --
|1 Todorova
|p 3749 -
|2 Crossref
|t Cancer Res.
|v 79
|y 2019

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21